Welcome to the e-CCO Library!

P647: Is liver steatosis a risk factor for hepatotoxicity in patients with inflammatory bowel disease on thiopruines?
Year: 2018
Source: ECCO '18 Vienna
Authors:

J. Phillips1, R. Preskey2*, C. Penfold3, J. Tyrrell-Price1, F. Gordon4

Created: Thursday, 21 February 2019, 9:14 AM
P647: Outcomes following the use of vedolizumab first line versus second line in Ulcerative Colitis: a single centre experience
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Almas, S.(1);Al-Talib, I.(1)*;Rahman, C.(1);Ansari, M.(1);Jones, J.(1);Slater, J.(1);King, D.(1);De Silva, S.(1);
Created: Friday, 14 July 2023, 11:12 AM
P647: Tuberculosis in patients treated with vedolizumab: clinical trial and post-marketing case series
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Zerôncio M.*1, Blake A.2, Rana-Khan Q.3, Palo W.4, Bhayat F.5

Created: Wednesday, 20 February 2019, 10:36 AM
P648 Efficacy including rapid response and safety of tofacitinib in Japanese patients with ulcerative colitis: A preliminary investigation in a specialised IBD centre
Year: 2020
Source:

ECCO'20 Vienna

Authors:

K. WatanabeAssistant Professor1, M. Kawai2, R. Koshiba2, K. Fujimoto2, K. Kojima2, K. Kaku2, N. Kinoshita2, T. Sato1, K. Kamikozuru2, Y. Yokoyama2, T. Miyazaki2, N. Hida2, S. Nakamura2

Created: Thursday, 30 January 2020, 10:12 AM
P648: Anti-TNF-α therapy, use of corticosteroids, and colectomy among paediatric and adolescent patients with ulcerative colitis: a nationwide study
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

K. Lund*1,2, M. D. Larsen1, T. Knudsen3,4, J. Kjeldsen5,6, R. G. Nielsen7,8, B. M. Noergaard1,2

Created: Friday, 22 February 2019, 9:41 AM
P648: Clinical feasibility of dried blood sampling for infliximab in IBD patients
Year: 2018
Source: ECCO '18 Vienna
Authors:

S. Berends1,2*, G. D'Haens2, K. Bloem3,4, J. Schaap4, A. De Vries4, T. Rispens3,4, R. Mathôt1

Created: Thursday, 21 February 2019, 9:14 AM
P648: Effectiveness of Biologic Therapies in Decreasing Risk of Hospitalization and Surgery, Maintaining Steroid Free Remission and Achieving Mucosal Healing in Inflammatory Bowel Disease; Real World Data.
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Shehab, M.(1)*;Abdullah, I.(1);Alostad, W.(1);Marei, A.(1);Alfadhli, A.(1);
Created: Friday, 14 July 2023, 11:12 AM
P648: Physical and mental health during COVID-19 quarantine in adolescents with chronic immunocompromised conditions and inflammatory bowel disease
Year: 2021
Source: ECCO'21 Virtual
Authors: Lindoso, L.(1);Oba, J.(1);Miranda, L.C.A.(1);Deboni, M.(1);Jiro Ozaki, M.(1);Lima, D.C.C.(1);Queiroz, L.B.(1);Astley, C.(2);Gualano, B.(2);Polanczyk, G.V.(3);K. Toma, R.(1);da Silva, C.A.A.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P648: Prevalence and Impact of Alcohol Consumption and Cannabis Use on Inflammatory Bowel Diseases
Year: 2022
Source: ECCO'22
Authors: Martinho-Grueber, M.(1);Kapoglou, I.(2);Bravo, F.(2);Sarraj, R.(2);Benz, E.(2);Restellini, S.(3);Biedermann, L.(4);Rogler, G.(4);Vavricka, S.R.(4);Schoepfer, A.(5);Maillard, M.(5);Michetti, P.(1);Brunner, F.(2);Clair, C.(6);Barry, M.P.(6);Von Kaenel, R.(7);JuilleratMSc, P.(2);
Created: Friday, 11 February 2022, 3:56 PM
P648: The impact of infliximab therapeutic drug monitoring on decisions made in a virtual biologics clinic for IBD
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Selinger C.*1, Lenti M.1, Clark T.1, Rafferty H.1, O'Connor A.1, Ahmad T.2, Hamlin J.1

Created: Wednesday, 20 February 2019, 10:36 AM
P649 Dietary habits in patients with inactive Crohn’s disease: Results of a controlled study
Year: 2020
Source:

ECCO'20 Vienna

Authors:

N. Ben Mustapha, H. Ben Youssef, A. Labidi, M. Hafi, M. Fekih, M. Serghini, J. Boubaker

Created: Thursday, 30 January 2020, 10:12 AM
P649: Anti-TNF agent drug survival in patients with IBD: real-world comparisons of individual anti-TNF agents based on the Swedish National Quality Registry for IBD (SWIBREG)
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

I. Visuri*1, C. Eriksson1, E. Mårdberg1, O. Grip2, A. Gustavsson3, H. Hjortswang4,5, P. Karling6, S. Montgomery7,8,9, P. Myrelid4,10, O. Olén9,11,12, The SWIBREG Study Group1, J. F. Ludvigsson13,14, J. Halfvarson1

Created: Friday, 22 February 2019, 9:41 AM
P649: Comparison of the KU Leuven ustekinumab concentration assay and the antibodies-to-ustekinumab assay with assays developed at Janssen R&D and used in clinical studies of IBD patients
Year: 2018
Source: ECCO '18 Vienna
Authors:

J.C. Marini1, A. Gils2*, G. Shankar1, M. Peeters2, E. Brouwers2, P. van Iperen3, M. Le Bars4, G.S. Bevalander3, B. Sattin5, S. Sloan6

Created: Thursday, 21 February 2019, 9:14 AM
P649: Does serum triiodothyronine-to-thyroxine (T3/T4) ratio predict therapeutic outcome to anti-TNF therapies in biologic-naïve patients with active luminal Crohn's disease?
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Carbery, I.(1)*;Lin, S.(2);Chanchlani, N.(2);Janjua, M.(2);Nice, R.(3);McDonald, T.J.(3);Bewshea, C.(4);Kennedy, N.A.(2);Ahmad, T.(2);Goodhand, J.R.(2);Selinger, C.P.(1);
Created: Friday, 14 July 2023, 11:12 AM
P649: Does switching to low dose thiopurine and allopurinol prevent IBD patients with evidence of hypermethylation on standard dose thiopurines from developing hepatotoxicity and drug side effects?
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Wade K., Johnson H., Slinger K., Hovell C., Weaver S., McLaughlin S.

Created: Wednesday, 20 February 2019, 10:36 AM
P649: The impact of COVID-19 on quality of life among patients with inflammatory bowel diseases – A Danish prospective population-based cohort study
Year: 2022
Source: ECCO'22
Authors: Attauabi, M.(1,2,3);Dahlerup, J.F.(4);Poulsen, A.(5);Hansen, M.R.(6);Vester-Andersen, M.K.(7);Eraslan, S.(2);Prahm, A.P.(5);Pedersen, N.(8);Larsen, L.(9);Jess, T.(9,10);Neumann, A.(11);Haderslev, K.V.(12);Molazahi, A.(13);Lødrup, A.B.(14);Glerup, H.(15);Oppfeldt, A.M.(16);Jensen, M.D.(17);Theede, K.(1,3);Kiszka-Kanowitz, M.(1,3);Seidelin, J.B.(2);Burisch, J.(1,3);
Created: Friday, 11 February 2022, 3:56 PM
P650 Outcomes of endoscopic balloon dilation for luminal strictures in Crohn’s disease
Year: 2020
Source:

ECCO'20 Vienna

Authors:

R. Sarraj, M. Martinho, F. Bravo, E. Benz, P. Juillerat

Created: Thursday, 30 January 2020, 10:12 AM
P650: A trend to higher adoption of mesalazine suppository use for UC patients in 15 European countries
Year: 2021
Source: ECCO'21 Virtual
Authors: Mackenzie-Smith, L.(1);Wüthrich, H.(2);Laoun, R.(2);
Created: Wednesday, 2 June 2021, 4:12 PM
P650: Combination therapy for perianal fistulising Crohn’s disease in biological era: What is the optimal time for surgical intervention?
Year: 2018
Source: ECCO '18 Vienna
Authors:

P. Zhu, B.L. Yang*

Created: Thursday, 21 February 2019, 9:14 AM